亚辉龙收盘下跌1.54%，滚动市盈率35.74倍，总市值87.79亿元

Company Overview - Shenzhen Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay technology [2] - The company has developed a fully automated immunoassay system, breaking the technological monopoly of foreign giants in the field of acridine ester direct chemiluminescence [2] - Aihuilong's quality management system meets international standards, with major products certified by ISO9001, ISO13485, and EU CE [2] Financial Performance - For Q1 2025, the company reported revenue of 418 million yuan, a year-on-year decrease of 3.13%, and a net profit of 10.148 million yuan, down 84.63% year-on-year, with a gross margin of 59.49% [2] - The current stock price is 15.39 yuan, with a rolling PE ratio of 35.74 times, and a total market capitalization of 8.779 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 59.49 times, with a median of 40.19 times, placing Aihuilong at the 69th position among its peers [1][3] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to its peers [3]